Sleepless Nights: Sanofi-Aventis Gets "Complete Response" Letter For Insomnia Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks Sanofi for more benefit-risk information for eplivanserin before approval.
You may also be interested in...
Somaxon Sleep Aid Silenor Not Effective, FDA Says
In its second "complete response" letter for the chronic insomnia drug, FDA says Silenor fails to meet approval standards.
Somaxon Sleep Aid Silenor Not Effective, FDA Says
In its second "complete response" letter for the chronic insomnia drug, FDA says Silenor fails to meet approval standards.
Transcept's Intermezzo Yields To FDA Concerns Over Residual Side Effects
Transcept's low-dose zolpidem for middle-of-the-night awakenings may need additional studies, including driving tests.